New topic: I decided to give us a shot of entering into into a different thread starting with a post on some of the research to date in support of Idronoxil – the active agent in the NOX66 unique (breakthrough?) delivery system.
[This post is lengthy, but is actually a summary because there is heaps of information out there in the scientific literature that could aid an investor researching NOX. I have my own notes, and the following is just quickly cobbled together from that with a bit of time put in to help it flow better…couldn't make it entirely comprehensive due to the time it ended up taking to collate, but I trust it reads ok J
For this ease of reading and the fact that this is a forum, not a scientific journal, I didn't include citations but can provide if anyone is interested.]
NOX66, what is it?
NOX themselves have released adequate information on the active pharmacological component of NOX66 - namely Idronoxil (aka Phenoxodial) for investors. But a bit of background to start.
Phenoxodial was derived from research into the very broad class of plant chemicals named Flavonoids - the single largest chemical class in the plant kingdom with over 5000 being noted to exist. Importantly, many are biologically active and play a role in functions involving plant growth and reproduction.
Research within the Flavonoid ground led to a focus on a sub-group called "Isoflavones" - of which there are over 1000 identified. Isoflavones are present in the diet in bean and bean product foods especially (soy has high concentrations), and epidemiological studies have indicated their positive contributions to health: for example the far better prostate health of eastern men vs western men is believed to be dictated by larger quantities of isoflavones in the diet.
A generally accepted observation is that an inverse relationship exists between dietary intake of isoflavones and cancer incidence. Once this link was discovered, scientific research in the area became intense during the 90's.
Long story short : Many strong candidates for anti-cancer study emerged in a lab setting based from molecules within the Isoflavone family, and Phenoxodiol (a synthetic derivative of Genistein created from work within this setting - aka Idronoxil) proved to be a lead candidate in this respect.
Idronoxil/Phenoxodiol (PXD)
Importantly, PXD was found to be non-toxic to human cells in vitro, and clinical trials to date have shown it to be safe for use in humans at some reasonably high doses, with no significant side effects.
Secondly, In a lab setting matched up against various cancer lines, ["In Vitro testing"] PXD kicks some serious ass:
- The toxic effect of PXD is shown to target only cancer cells - likely due to cell cycle inhibition triggered within the cancer cells, speculated to result from a cancer cell membrane component (ENOX2 /ENOX1 ?). The mechanism of action is still an area where studies are making ground in more fully understanding.
- "Low concentrations of phenoxodiol exhibited broadly acting antiproliferative effects against most tumour cell lines tested".
- Chemoresistant ovarian cancer cells were obtained from patients and cultured in one study. PXD restored the sensitivity of ovarian cancer cell cultures to apoptosis. (Cancer cells grow uncontrollably, and resist apoptosis/cell death)
-PXD exhibits anti-angiogenic properties. In mice, new vessel formation was inhibited in the presence of PXD.
Chemoresistance
Further studies combined cancer cell lines with typical chemotherapy drugs to investigate outcomes.
- Ten Epithelial Ovarian Carcinoma (EOC) cell lines were tested against chemo drugs alone (control), PXD alone, and chemo drugs & PXD. Results indicated that PXD could chemosensitise EOC cells to commonly used chemotherapeutic agents : PXD enhanced the cytoxic effects of carboplatin, paclitaxel and gemcitabine, but also reduced the dose of the drug necessary to obtain an effective anti-tumour effect. (see image)
This study also showed tumours implanted into mice, when treated with PXD and Chemo combinations showed responses over 10 days in size and mass reduction - with a 70%+ reduction in mass in a PXD and paclitaxel combination. (see image)
- PXD treatment sensitised Melanoma cultures developed from patients to carboplatin in another study. (see image)
Clinical Studies
Phase I trials indicated that PXD is well tolerated in IV infusion administration up to 30mg/kg over 6 weeks.
Phase II trials results : best summarised in attached image. (If attaching it worked)
PXD, PXD/Chemo combinations responses listed to RHS of table, and include some partial responses and stable disease states.
NOX66
As indicated in releases NOX66 is a unique, untrialled delivery for idronoxil, designed to avoid what is believed to be the "metabolism issues" associated with the oral and IV administrations executed to date in clinical trials, and instead deliver the drug in its active form to the target site on the tumour cell. Investors are looking forward to the outcomes from these trials.
*These are broad notes on detailed clinical studies – methodologies should be investigated in a DYOR manner J
(20min delay)